Human Papillomavirus (HPV) Self-Sampling among Never-and Under-Screened Indigenous Māori, Pacific and Asian Women in Aotearoa New Zealand: A Feasibility Study.
HPV
Kaupapa Māori Research
cervical cancer screening
equity
indigenous health research
self-sampling
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
24 09 2021
24 09 2021
Historique:
received:
29
06
2021
revised:
13
09
2021
accepted:
13
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
In Aotearoa, New Zealand, the majority of cervical cancer cases occur in women who have never been screened or are under-screened. Wāhine Māori, Pacific and Asian women have the lowest rate of cervical screening. Self-sampling for human papillomavirus (HPV-SS) has been shown to increase participation in cervical cancer screening. A whole-of-system approach, driven by evidence in the most effective delivery of HPV-SS, is required to mitigate further widening of the avoidable gap in cervical screening access and outcomes between groups of women in Aotearoa. This single-arm feasibility and acceptability study of HPV self-sampling invited never- and under-screened (≥5 years overdue) 30-69-year-old women from general practices in Auckland, Aotearoa. Eligible women were identified by data matching between the National Cervical Programme (NCSP) Register and practice data. Focus groups were additionally held with eligible wāhine Māori, Asian and Pacific women to co-design new patient information materials. Questionnaires on HPV knowledge and post-test experience were offered to women. Our follow-up protocols included shared decision-making principles, and we committed to follow-up ≥90% of women who tested positive for HPV. Data matching identified 366 eligible never- and under-screened wāhine Māori, Pacific and Asian women in participating practices. We were only able to contact 114 women, and 17, during the discussion, were found to be ineligible. Identifying and contacting women overdue for a cervical screen was resource-intensive, with a high rate of un-contactability despite multiple attempts. We found the best uptake of self-sampling was at focus groups. Of the total 84 HPV-SS tests, there were five positive results (6%), including one participant with HPV18 who was found to have a cervical Adenocarcinoma at colposcopy. In our feasibility study, self-sampling was acceptable and effective at detecting HPV and preventing cervical cancer in under-screened urban wāhine Māori, Pacific and Asian women in Aotearoa. This is the first report of cervical Adenocarcinoma (Grade 1B) as a result of an HPV-18 positive self-sample in Aotearoa. We co-designed new patient information materials taking a health literacy and ethnicity-specific approach. This work provides policy-relevant information to the NCSP on the resources required to implement an effective HPV self-sampling programme to improve equity in national cervical cancer screening.
Identifiants
pubmed: 34639352
pii: ijerph181910050
doi: 10.3390/ijerph181910050
pmc: PMC8507781
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
BMJ. 2018 Dec 5;363:k4823
pubmed: 30518635
Gynecol Oncol. 2019 Mar;152(3):472-479
pubmed: 30876491
PLoS One. 2020 Jun 15;15(6):e0234536
pubmed: 32542004
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
Prev Med. 2021 Mar;144:106314
pubmed: 33678228
Clinics (Sao Paulo). 2017 Mar;72(3):183-187
pubmed: 28355365
Eur J Cancer Care (Engl). 2021 Mar;30(2):e13380
pubmed: 33280179
BMC Cancer. 2014 Mar 19;14:207
pubmed: 24646201
J Clin Virol. 2020 Jun;127:104375
pubmed: 32361328
BMJ Glob Health. 2019 May 14;4(3):e001351
pubmed: 31179035
Global Health. 2017 Sep 5;13(1):69
pubmed: 28870225
BMJ Open. 2016 Apr 25;6(4):e010660
pubmed: 27113237
N Z Med J. 2018 Mar 23;131(1472):53-63
pubmed: 29565936
J Immigr Minor Health. 2020 Aug;22(4):852-859
pubmed: 31828485
N Z Med J. 2019 Jun 21;132(1497):21-31
pubmed: 31220062
Int J Equity Health. 2018 Feb 20;17(1):28
pubmed: 29458379
Front Public Health. 2018 Apr 09;6:77
pubmed: 29686981
J Gen Intern Med. 2012 Oct;27(10):1361-7
pubmed: 22618581
BMC Cancer. 2019 Dec 9;19(1):1198
pubmed: 31815615
Cancer Causes Control. 2017 Dec;28(12):1393-1404
pubmed: 28986722
Clin Microbiol Infect. 2015 Sep;21(9):817-26
pubmed: 25936581
Sex Health. 2015 Aug;12(4):279-86
pubmed: 26028338
Cancers (Basel). 2020 Apr 24;12(4):
pubmed: 32344565
J Public Health (Oxf). 2017 Sep 1;39(3):601-608
pubmed: 27412177
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
Aust N Z J Obstet Gynaecol. 2019 Apr;59(2):301-307
pubmed: 30614524
BMC Health Serv Res. 2020 May 11;20(1):398
pubmed: 32393243
BMC Cancer. 2015 Nov 04;15:849
pubmed: 26536865
Lancet Reg Health West Pac. 2021 Sep 07;16:100265
pubmed: 34590066
Aust N Z J Obstet Gynaecol. 2021 Feb;61(1):135-141
pubmed: 33350455
BMC Med Inform Decis Mak. 2013;13 Suppl 2:S10
pubmed: 24624970
Health Equity. 2019 Feb 14;3(1):22-29
pubmed: 30783634